阿托伐他汀联合缬沙坦对慢性肾炎的疗效及安全性评价

Efficacy and safety evaluation of atorvastatin combined with valsartan on chronic nephritis

目的评估阿托伐他汀联合缬沙坦对慢性肾炎的疗效及安全性。方法选取2015年5月~2017年5月间在本院治疗的92例慢性肾炎患者作为研究对象,采用随机数字表法将患者分为研究组和对照组,各46例,两组患者均应用缬沙坦进行治疗,研究组患者在此基础上增用阿托伐他汀,观察两组患者治疗效果,包括治疗有效率、肾功能相关指标及不良反应发生率。结果治疗后,研究组患者Scr、BUN水平与对照组相近,差异无统计学意义(P>0.05);治疗后,研究组患者24 h pro、CRP水平均低于对照组,差异有统计学意义(P<0.05);研究组治疗有效率高于对照组,差异有统计学意义(P<0.05);研究组患者不良反应发生率与对照组相近,差异无统计学意义(P>0.05)。结论阿托伐他汀联合缬沙坦对慢性肾炎患者疗效较好,安全性较高,值得广泛推荐。

Objective To evaluate the efficacy and safety of atorvastatin combined with valsartan on chronic nephritis. Methods A total of 92 chronic nephritis patients treated in our hospital from May 2015 to May 2017 were selected in this study. The patients were divided into study group and control group by random number table method, with 46 cases in each group. Both groups of patients were treated with valsartan. And the study group was treated with atorvaslatin on the above basis. The treatment effects of patients in two groups were observed. The observation indicators included treatment efficiency, renal function related indicators and the incidence of adverse reactions. Results After treatment, the levels of Scr and BUN in the study group were similar to those in the control group, and the difference was no sta- tistically significant （P〉0.05）. After treatment, the levels of 24 h pro and CRP in the study group were significantly lower than those in the control group, and the difference was statistically significant（P〈0.05）. The effective rate of treat- ment in study group was higher than that in control group, and the difference was statistically significant （P〈0.05）. The incidence of adverse reactions in study group was similar to that in control group, the difference was no statistically sig- nificant（P〉0.05）. Conclusion Atorvastatin combined with valsartan is effective and safe for patients with chronic nephritis, which is worthy of wide recommendation.